** Brokerage Wells Fargo initiates coverage on medtech firm LeMaitre Vascular LMAT.O with an "equal weight" rating and a PT of $95
** Brokerage says LMAT could be poised for growth in 2025 if it pursues strategic mergers and acquisitions; adds that the company has $300 million available for deals that could bolster its device portfolio
** Wells Fargo observes LMAT may acquire companies that make surgical sealants, devices that block blood flow and clips for tying off blood vessels
** "We believe that the stock fully prices in an optimistic outlook for pricing and volume growth in 2025 and beyond" - brokerage
** Stock up about 55% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。